Form 4: BDX Executive Sells Shares Under Pre-Arranged 10b5-1 Plan

Becton Dickinson & Co. EVP Michael Feld sold 57 shares of common stock for $197.99 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Feld, EVP & President, Life Sciences at Becton Dickinson and Company (BDX), sold 57 shares of common stock.
• The transaction occurred on August 22, 2025, at a price of $197.99 per share.
• Following the sale, Michael Feld beneficially owns 8,360 shares of BDX common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Feld on August 2, 2024.

Sentiment

Score: 5

Explanation: The sale of a small number of shares by an executive under a pre-arranged 10b5-1 plan is a routine event and does not typically signal a significant change in company outlook or executive confidence.

Positives

• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a reaction to recent non-public information, which can mitigate concerns about insider selling.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the executive's direct equity stake in the company, which some investors might interpret as a slight reduction in alignment of interests.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitors.

Comparison to Industry Standards

• This filing is a standard disclosure of an insider stock transaction.
• The use of a Rule 10b5-1 plan is a common practice among executives to manage personal finances while complying with insider trading regulations.
• Many executives at large-cap companies like Johnson & Johnson, Medtronic, or Abbott Laboratories also utilize 10b5-1 plans for planned stock sales.

Related Party Transactions

• The reported transaction is an insider sale by an executive, which is a type of related party transaction.

Stakeholder Impact

• Shareholders: A minor reduction in executive ownership, but the 10b5-1 plan suggests it's for personal financial planning rather than a lack of confidence. The impact is likely minimal given the small number of shares relative to the company's market capitalization.
• Employees, Customers, Suppliers, Creditors: No direct impact from this routine insider transaction.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled insider sale of a very small number of shares by an executive. Such transactions, especially when executed under a 10b5-1 plan, are typically for personal financial management and do not provide significant new information to warrant a change in investment thesis. The company's fundamental outlook remains unchanged based on this filing.

Keywords

Becton Dickinson, BDX, Michael Feld, Insider Trading, Form 4, 10b5-1 Plan, Stock Sale, Executive Compensation, Life Sciences